Redefining possibilities in the fight against cancer
Sanavia blends advanced scientific research and breakthrough technologies with a compassionate, patient-centered approach.
Our Team
We’re a New York-based biotech company with a team of drug developers from Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine, and Columbia University.
Our Mission
The majority of cancer patients don’t benefit from current therapies due to drug resistance. We’re developing novel immunotherapies that can safely and effectively overcome drug resistance and improve patients' lives.
Our Validation Process
We combine high throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling, and artificial intelligence with novel in vivo models to validate targets and develop immunotherapies that can safely and effectively eliminate drug-resistant tumors.
Our Discovery Platform
We use our proprietary platform to discover unexplored, clinically relevant, cancer-specific epitopes in different types of drug resistant tumors and to generate antibodies with atomic-level specificity to these epitopes.
Guided by compassion. Powered by expertise.
Discover Sanavia
Let's connect &
transform oncology
We believe in the power of connections and the transformation they can bring. We look forward to connecting with you and working together to revolutionize the future of oncology.
Want to learn more about our science, interested in working with us, or have a question?
We welcome partnerships with researchers, healthcare professionals, and organizations that drive innovation and advance the field of oncology.